TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07778498: A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors.

Sponsor: Phrontline Biopharma · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,563,630

Rescue Site Savings

+$6,990,060

Unlock Full NCT07778498 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07778498 Rescue Dossier →